HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Growth of 340B program triggers ‘battle over big money’
-
- Mindfulness meditation improved quality of life in adolescents with cancer Christine A. Zawistowski, MD
- A 54-year-old woman with bilateral hydronephrosis Ramya Varadarajan, MD
- Cancer trials: Lies, damned lies and statistics Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Zydelig for CLL, SLL, follicular lymphoma
- Two mutations linked to success of adoptive T-cell therapy in melanoma
- Sarcopenia increased risk for mortality after radical cystectomy for bladder cancer
- Shift in NSCLC trial design, interpretation linked to inefficiency
- Addition of oxaliplatin to folinic acid-modulated fluorouracil extended survival in pancreatic cancer
-
- Catheter-directed thrombolysis did not benefit, may harm patients with DVT
- Classifier preoperatively identified medullary thyroid cancer
- Double mastectomy decreased mortality among women with BRCA mutations
- H. pylori eradication failed to reduce risk for gastric cancer after resection
- HPV status predicted OS after progression in oropharyngeal cancer
- MRD may guide augmented post-remission treatment in pediatric ALL
- Multifaceted intervention improved colorectal cancer screening adherence
- Patients with HIV, cancer less likely to receive oncology treatment
-
- PET/CT predicted outcomes in primary mediastinal large B-cell lymphoma
- Recurrent VTE linked to certain cancers, leg paresis
- 30% of breast cancer survivors unemployed 4 years after treatment
- Letermovir reduced cytomegalovirus infection after HSCT
- Modafinil no different than placebo for fatigue reduction in NSCLC
- ASTRO announces 2014 fellows class
- City of Hope appoints new board of directors chair
- Rutgers director receives award
-
- Melanoma researcher joins cancer institute
- St. Jude researcher receives ASCO award